CBP-174 is a small molecule inhibitor of a G-protein coupled receptor involved in pruritus due to chronic skin inflammation. It has a completely different mode of action from the commonly used antihistamines and is designed to offer therapeutic benefits that traditional antihistamines do not provide. The drug candidate was selected from a lead portfolio in-licensed from Arena Pharmaceuticals (NASDAQ:ARNA). Our preclinical studies demonstrated that the compound is highly potent and selective, and is highly efficacious in the relevant preclinical models. This compound has the potential to be first-in-class. It is currently in preclinical development.

TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower